Mechanism of neonatal thrombocytopenia focusing on thrombopoietin and its novel treatment

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K19697
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Aichi Medical University
• Principal Investigator: Takeshita Satoru 愛知医科大学, 医学部, 助教 (20715875)
• Research Collaborator: Aoyama Mineyoshi
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 新生児 / 血小板 / トロンボポエチン / トロンボポエチン受容体

Outline of Final Research Achievements

The cause of early birth thrombocytopenia in Small-for-Gestetional Age (SGA) infant was unknown. In this study, we focused on thrombopoietin, which is involved in thrombopoiesis, and divided it into preterm infants and full term infants, SGA children and non-SGA children and clarified the pathological condition. There was no rise in thrombopoietin in SGA children, suggesting thrombopoietin involving to thrombocytopenia in infants. Next, in order to conduct experiments using model rats of SGA children, model rats were created. The research results were presented at the academic meetings of relevant academic societies.

Free Research Field

新生児医学

Academic Significance and Societal Importance of the Research Achievements

早期新生児における血小板減少症の原因は、多くが不明であり血小板輸血など対症療法にとどまっている。原因を明らかにすることで輸血に依存しない新たな治療薬の開発につながる。輸血の代替治療の研究は、医療社会資源の限られた現代において有益であると考えている。